Apellis Pharmaceuticals, Inc. 4

Mark Jeffrey DeLong, Chief Business & Strategy Officer of Apellis Pharmaceuticals, Inc., had all 114,591 shares of common stock and all outstanding RSUs and stock options effectively cashed out or canceled for cash and contingent value rights in connection with Biogen’s merger at $41.00 per share plus CVRs.

On May 14, 2026, in connection with the closing of Biogen Inc.’s acquisition of Apellis Pharmaceuticals, Inc., Chief Business & Strategy Officer Mark Jeffrey DeLong’s equity holdings were converted and canceled pursuant to the merger agreement rather than through open‑market trading. His previously held 114,591 shares of Apellis common stock were converted into the right to receive $41.00 in cash per share plus one contingent value right (CVR) per share, and his outstanding restricted stock unit awards (both time‑based and performance‑based, including January 2026 TSR‑linked grants that paid out at 200% of target) were similarly canceled and converted into cash and CVRs payable on the original vesting schedules, with performance conditions removed. In addition, multiple tranches of vested and unvested stock options with exercise prices below $41.00 were canceled for cash equal to the in‑the‑money value plus CVRs per underlying share, options with exercise prices between $41.00 and $45.00 were canceled for CVRs only, and deeply out‑of‑the‑money options with exercise prices at or above $45.00 were canceled without consideration. Following these transactions, DeLong no longer holds Apellis equity, as the company became a wholly owned subsidiary of Biogen and his equity positions were fully cashed out and/or exchanged for CVR entitlements.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224597

Alert Tier

6